Clay Siegall is among the founding fathers of Seattle Genetics. This company is involved with biotechnological research with the motive of helping patients of cancer. Currently, Siegall works as the SEO of the company. Siegall is a scientist who specializes in cancer treatments. After graduating with a Genetics Ph.D. from George Washington University, Siegall jump started his career working as an investigator of research at the Bristol/Myers Squibb Pharmaceutical Research Institute. While working here, he was promoted to the post of a principle scientist. He later went on to earn the title of “National Cancer Institute” fellow.
Siegall’s Role in Seattle Genetics
As the CEO of Seattle Genetics, Siegall has led the company to be regarded as a leading authority in the study and manufacture of “antibody-drug conjugates”. It is under his tenure that Seattle Genetics received FDA approval for ADCETRIS. Later on, ADCETRIS merged with Takeda Pharmaceutical to form an international product that is acknowledged in over 65 countries across the globe.
Siegall can also take credit for helping Seattle Genetics receive multiple licenses in connection with the ADCETRIS product. Siegall’s influence has resulted in licenses from AbbVie, GlaxoSmithKline, Pfizer, and Genentech. Dr Siegall further helped Seattle Genetics amass over $1.2 billion in capital from private and public sources. In 2001, Siegall played a central role in Seattle Genetics IPO launch.
Siegall’s Role in Cancer Research
Siegall’s prosperous career is attributed to his efforts and achievements with regards to cancer research. Siegall’s hard work, dedication, and commitment have all been directed to identifying a cancer cure. It is his desire to find a solution to this life threatening condition that caused him to champion research on alternative treatments. Siegall has been involved in several medical and scientific committees that are focused on addressing the cancer menace. His full involvement in the fight against cancer caused him to receive an award given every year to the University of Maryland Alumni for math, natural sciences, and computers. He had initially been awarded with the “Pacific Northwest Ernst and Young Entrepreneur of the Year”.
Apart from receiving coveted awards, Siegall owns 15 patents and is set to have more as he continues his journey in the search for a cancer cure. His publications address his discoveries and the progress of his research. These publications have helped the health sector identify more efficient and effective cancer treatments.